mTOR inhibitors for treatment of low-risk prostate cancer-Reference-Cited by-同舟云学术

mTOR inhibitors for treatment of low-risk prostate cancer

Published:2018-08 Issue: Volume:117 Page:63-68
ISSN:0306-9877
Container-title:Medical Hypotheses
language:en
Short-container-title:Medical Hypotheses

Author:

Liss Michael A.,Rickborn Lanette,DiGiovanni John,Bacich Dean^ORCID,DeGraffenried Linda A.,Parihar Manish,Thompson Ian M.,Sharp Zelton Dave

Funder

Office of the Assistant Secretary of Defense for Health Affairs

NCI

Roger L. and Laura D. Zeller Charitable Foundation

Publisher

Elsevier BV

Subject

General Medicine

Reference87 articles.

1. Affairs UNDoEaS. Population Ageing and Development 2012. Available from: http://www.un.org/en/development/desa/population/publications/ageing/population-ageing-development-2012.shtml.

2. Interdisciplinary topics in gerontology and geriatrics,2013

3. Cancer statistics, 2017;Siegel;CA Cancer J Clin,2017

4. Hallmarks of cancer: the next generation;Hanahan;Cell,2011

5. mTOR signaling in disease;Dazert;Curr Opin Cell Biol,2011

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Immunologic and dose dependent effects of rapamycin and its evolving role in chemoprevention;Clinical Immunology;2022-12

2. Prostate Cancer Biomarkers: From diagnosis to prognosis and precision-guided therapeutics;Pharmacology & Therapeutics;2021-12

3. Novel Combinatorial Approaches to Tackle the Immunosuppressive Microenvironment of Prostate Cancer;Cancers;2021-03-08

4. Phase I Trial of Encapsulated Rapamycin in Patients with Prostate Cancer Under Active Surveillance to Prevent Progression;Cancer Prevention Research;2021-01-29

5. Sirolimus loaded polyol modified liposomes for the treatment of Posterior Segment Eye Diseases;Medical Hypotheses;2020-03